Related Experiment Videos
Subcortical vascular dementia
1Memory Research Unit, Department of Clinical Neurosciences, University of Helsinki, Finland. timo.erkinjuntti@huch.fi
Insights
Subcortical vascular dementia (VaD), a subtype of VaD, offers a more homogeneous group for clinical trials. Focusing on this specific form of VaD may lead to more predictable outcomes and treatment responses.
Area of Science:
- Neurology
- Neuroscience
- Vascular Medicine
Background:
- Vascular dementia (VaD) encompasses diverse vascular mechanisms, brain changes, causes, and clinical presentations.
- Current VaD diagnostic criteria result in etiological and clinical heterogeneity, impacting clinical trial efficacy.
- This heterogeneity poses challenges for drug development and treatment strategies in VaD research.
Purpose of the Study:
- To propose subcortical (ischaemic) VaD as a more homogeneous subgroup for clinical drug trials.
- To define the specific characteristics of subcortical VaD for improved research focus.
- To explore the potential for more predictable clinical outcomes and treatment responses within this subtype.
Main Methods:
- Review and synthesis of existing literature on VaD subtypes and diagnostic criteria.
- Identification of key pathological and clinical features distinguishing subcortical VaD.
- Analysis of the implications of definitional homogeneity for clinical trial design.
Main Results:
- Subcortical VaD is characterized by small vessel disease, lacunar infarcts, and white matter lesions in subcortical brain regions.
- This subtype integrates 'Binswanger's disease' and 'the lacunar state' under a unified definition.
- A homogeneous group is expected to yield more predictable clinical pictures and natural histories.
Conclusions:
- Focusing on subcortical VaD offers a viable strategy to address the heterogeneity challenge in VaD research.
- This approach may enhance the predictability of clinical trial results and treatment responses.
- Further research into subcortical VaD could refine diagnostic and therapeutic strategies for vascular dementia.
Abstract:
Vascular dementia (VaD) incorporates different vascular mechanisms and changes in the brain, and has different causes and clinical manifestations. Current criteria for VaD select an aetiologically and clinically heterogeneous group and this definitional heterogeneity has affected clinical trial results. Focus on a more homogeneous group, such as that with subcortical (ischaemic) VaD, could be an alternative in clinical drug trials. This subtype incorporates two small vessel clinical entities - 'Binswanger's disease' and 'the lacunar state'. It comprises small vessel disease as the primary vascular aetiology, lacunar infarct(s) and ischaemic white matter lesions as the primary type of brain lesions, subcortical location as the primary location of lesions, and the subcortical clinical syndrome as the primary clinical manifestation. Subcortical VaD is expected to show a more predictable clinical picture, natural history, outcome and treatment responses.